Remote evaluation of sleep to enhance understanding of early dementia due to Alzheimer's Disease (RESTED-AD): an observational cohort study protocol

被引:1
|
作者
Blackman, Jonathan [1 ,2 ]
Morrison, Hamish Duncan [1 ,2 ]
Gabb, Victoria [1 ,2 ]
Biswas, Bijetri [1 ]
Li, Haoxuan [1 ,2 ]
Turner, Nicholas [1 ]
Jolly, Amy [3 ]
Trender, William [3 ]
Hampshire, Adam [3 ]
Whone, Alan [2 ]
Coulthard, Elizabeth [1 ,2 ,4 ]
机构
[1] Univ Bristol, Bristol Med Sch, Bristol BS2 8DZ, England
[2] North Bristol NHS Trust, Bristol Brain Ctr, Bristol BS10 5NB, England
[3] Imperial Coll London, Fac Med, London SW7 2AZ, England
[4] Univ Bristol, Southmead Hosp, Bristol Med Sch, Learning & Res Bldg, Bristol BS10 5NB, England
关键词
Alzheimer's disease; AD; Mild cognitive impairment; MCI; Dementia; Sleep; Circadian; Infradian; EEG; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; COGNITIVE PERFORMANCE; NATIONAL INSTITUTE; OREXIN; OLDER; RECOMMENDATIONS; DISTURBANCES; EPIDEMIOLOGY; IMPAIRMENT;
D O I
10.1186/s12877-023-04288-0
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
BackgroundSleep and circadian rhythm disorders are well recognised in both AD (Alzheimer's Disease) dementia and MCI-AD (Mild Cognitive Impairment due to Alzheimer's Disease). Such abnormalities include insomnia, excessive daytime sleepiness, decreased sleep efficiency, increased sleep fragmentation and sundowning.Enhancing understanding of sleep abnormalities may unveil targets for intervention in sleep, a promising approach given hypotheses that sleep disorders may exacerbate AD pathological progression and represent a contributory factor toward impaired cognitive performance and worse quality of life. This may also permit early diagnosis of AD pathology, widely acknowledged as a pre-requisite for future disease-modifying therapies.This study aims to bridge the divide between in-laboratory polysomnographic studies which allow for rich characterisation of sleep but in an unnatural setting, and naturalistic studies typically approximating sleep through use of non-EEG wearable devices. It is also designed to record sleep patterns over a 2 month duration sufficient to capture both infradian rhythm and compensatory responses following suboptimal sleep. Finally, it harnesses an extensively phenotyped population including with AD blood biomarkers.Its principal aims are to improve characterisation of sleep and biological rhythms in individuals with AD, particularly focusing on micro-architectural measures of sleep, compensatory responses to suboptimal sleep and the relationship between sleep parameters, biological rhythms and cognitive performance.BackgroundSleep and circadian rhythm disorders are well recognised in both AD (Alzheimer's Disease) dementia and MCI-AD (Mild Cognitive Impairment due to Alzheimer's Disease). Such abnormalities include insomnia, excessive daytime sleepiness, decreased sleep efficiency, increased sleep fragmentation and sundowning.Enhancing understanding of sleep abnormalities may unveil targets for intervention in sleep, a promising approach given hypotheses that sleep disorders may exacerbate AD pathological progression and represent a contributory factor toward impaired cognitive performance and worse quality of life. This may also permit early diagnosis of AD pathology, widely acknowledged as a pre-requisite for future disease-modifying therapies.This study aims to bridge the divide between in-laboratory polysomnographic studies which allow for rich characterisation of sleep but in an unnatural setting, and naturalistic studies typically approximating sleep through use of non-EEG wearable devices. It is also designed to record sleep patterns over a 2 month duration sufficient to capture both infradian rhythm and compensatory responses following suboptimal sleep. Finally, it harnesses an extensively phenotyped population including with AD blood biomarkers.Its principal aims are to improve characterisation of sleep and biological rhythms in individuals with AD, particularly focusing on micro-architectural measures of sleep, compensatory responses to suboptimal sleep and the relationship between sleep parameters, biological rhythms and cognitive performance.BackgroundSleep and circadian rhythm disorders are well recognised in both AD (Alzheimer's Disease) dementia and MCI-AD (Mild Cognitive Impairment due to Alzheimer's Disease). Such abnormalities include insomnia, excessive daytime sleepiness, decreased sleep efficiency, increased sleep fragmentation and sundowning. Enhancing understanding of sleep abnormalities may unveil targets for intervention in sleep, a promising approach given hypotheses that sleep disorders may exacerbate AD pathological progression and represent a contributory factor toward impaired cognitive performance and worse quality of life. This may also permit early diagnosis of AD pathology, widely acknowledged as a pre-requisite for future disease-modifying therapies.This study aims to bridge the divide between in-laboratory polysomnographic studies which allow for rich characterisation of sleep but in an unnatural setting, and naturalistic studies typically approximating sleep through use of non-EEG wearable devices. It is also designed to record sleep patterns over a 2 month duration sufficient to capture both infradian rhythm and compensatory responses following suboptimal sleep. Finally, it harnesses an extensively phenotyped population including with AD blood biomarkers.Its principal aims are to improve characterisation of sleep and biological rhythms in individuals with AD, particularly focusing on micro-architectural measures of sleep, compensatory responses to suboptimal sleep and the relationship between sleep parameters, biological rhythms and cognitive performance.BackgroundSleep and circadian rhythm disorders are well recognised in both AD (Alzheimer's Disease) dementia and MCI-AD (Mild Cognitive Impairment due to Alzheimer's Disease). Such abnormalities include insomnia, excessive daytime sleepiness, decreased sleep efficiency, increased sleep fragmentation and sundowning.Enhancing understanding of sleep abnormalities may unveil targets for intervention in sleep, a promising approach given hypotheses that sleep disorders may exacerbate AD pathological progression and represent a contributory factor toward impaired cognitive performance and worse quality of life. This may also permit early diagnosis of AD pathology, widely acknowledged as a pre-requisite for future disease-modifying therapies.This study aims to bridge the divide between in-laboratory polysomnographic studies which allow for rich characterisation of sleep but in an unnatural setting, and naturalistic studies typically approximating sleep through use of non-EEG wearable devices. It is also designed to record sleep patterns over a 2 month duration sufficient to capture both infradian rhythm and compensatory responses following suboptimal sleep. Finally, it harnesses an extensively phenotyped population including with AD blood biomarkers.Its principal aims are to improve characterisation of sleep and biological rhythms in individuals with AD, particularly focusing on micro-architectural measures of sleep, compensatory responses to suboptimal sleep and the relationship between sleep parameters, biological rhythms and cognitive performance.Methods/designThis observational cohort study has two arms (AD-MCI / mild AD dementia and aged-matched healthy adults). Each participant undergoes a baseline visit for collection of demographic, physiological and neuropsychological information utilising validated questionnaires. The main study period involves 7 nights of home-based multi-channel EEG sleep recording nested within an 8-week study period involving continuous wrist-worn actigraphy, sleep diaries and regular brief cognitive tests. Measurement of sleep parameters will be at home thereby obtaining a real-world, naturalistic dataset. Cognitive testing will be repeated at 6 months to stratify participants by longitudinal disease progression. DiscussionThis study will generate new insights particularly in micro-architectural measures of sleep, circadian patterns and compensatory sleep responses in a population with and without AD neurodegenerative change. It aims to enhance standards of remotely based sleep research through use of a well-phenotyped population and advanced sleep measurement technology.
引用
收藏
页数:11
相关论文
共 33 条
  • [21] Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD
    Hwang, Jihye
    Jeong, Jee Hyang
    Yoon, Soo Jin
    Park, Kyung Won
    Kim, Eun-Joo
    Yoon, Bora
    Jang, Jae-Won
    Kim, Hee Jin
    Hong, Jin Yong
    Lee, Jong-Min
    Park, Hyuntae
    Kang, Ju-Hee
    Choi, Yong-Ho
    Park, Gilsoon
    Hong, Jinwoo
    Byun, Min Soo
    Yi, Dahyun
    Kim, Yu Kyeong
    Lee, Dong Young
    Choi, Seong Hye
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03)
  • [22] ALUMNI AD Study Design: Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer's Disease
    Seleri, Sheila
    Brangman, Sharon
    Henderson, J. Neil
    Parker, Monica
    Monroe, Stephanie
    Mintzer, Jacobo
    Wise-Brown, Alexandria
    Grundman, Michael
    Smith, Janice
    Doody, Rachelle
    Lin, Helen
    Assman, Beverly
    Rippon, Gregory
    NEUROLOGY, 2023, 100 (17)
  • [23] Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker of Alzheimer's disease (DEBBIE-AD): a prospective observational multicohort study protocol
    Padrela, Beatriz
    Mahroo, Amnah
    Tee, Mervin
    Sneve, Markus H.
    Moyaert, Paulien
    Geier, Oliver
    Kuijer, Joost P. A.
    Beun, Soetkin
    Nordhoy, Wibeke
    Zhu, Yufei David
    Buck, Mareike A.
    Hoinkiss, Daniel C.
    Konstandin, Simon
    Huber, Jorn
    Wiersinga, Julia
    Rikken, Roos
    de Leeuw, Diederick
    Grydeland, Hakon
    Tippett, Lynette
    Cawston, Erin E.
    Ozturk-Isik, Esin
    Linn, Jennifer
    Brandt, Moritz
    Tijms, Betty M.
    van de Giessen, Elsmarieke M.
    Muller, Majon
    Fjell, Anders
    Walhovd, Kristine
    Bjornerud, Atle
    Palhaugen, Lene
    Selnes, Per
    Clement, Patricia
    Achten, Eric
    Anazodo, Udunna
    Barkhof, Frederik
    Hilal, Saima
    Fladby, Tormod
    Eickel, Klaus
    Morgan, Catherine
    Thomas, David L.
    Petr, Jan
    Gunther, Matthias
    Mutsaerts, Henk J. M. M.
    BMJ OPEN, 2024, 14 (03):
  • [24] Association of multiple metabolic and cardiovascular markers with the risk of cognitive decline and mortality in adults with Alzheimer's disease and AD-related dementia or cognitive decline: a prospective cohort study
    Liu, Longjian
    Gracely, Edward J.
    Zhao, Xiaopeng
    Gliebus, Gediminas P.
    May, Nathalie S.
    Volpe, Stella L.
    Shi, Jingyi
    DiMaria-Ghalili, Rose Ann
    Eisen, Howard J.
    FRONTIERS IN AGING NEUROSCIENCE, 2024, 16
  • [25] Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study
    Acosta-Baena, Natalia
    Sepulveda-Falla, Diego
    Mario Lopera-Gomez, Carlos
    Cesar Jaramillo-Elorza, Mario
    Moreno, Sonia
    Camilo Aguirre-Acevedo, Daniel
    Saldarriaga, Amanda
    Lopera, Francisco
    LANCET NEUROLOGY, 2011, 10 (03): : 213 - 220
  • [26] Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study
    Halminen, Olli
    Vesikansa, Aino
    Mehtala, Juha
    Horhammer, Iiris
    Mikkola, Teija
    Virta, Lauri J.
    Ylisaukko-oja, Tero
    Linna, Miika
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 81 (03) : 1103 - 1115
  • [27] Impact of hospital-based early detection on management in chronic kidney disease: the CKD Stewardship study (CKD-S) - protocol for a prospective, multicentre, observational cohort study
    Wynter, Lucinda Alix
    Smyth, Brendan
    Saunders, John
    Moroney, Carmen
    Gorringe, Lilijana
    Turner, Kylie
    Venugopal, Sreeram
    Tienstra, Lisa
    Monteverde, Rowena
    Kang, Amy
    Norris, Sarah
    Aouad, Leyla
    Sen, Shaundeep
    Mangos, George
    Chadban, Steven
    BMJ OPEN, 2025, 15 (03):
  • [28] Secular Trends in the Incidence of and Mortality Due to Alzheimer's Disease and Other Forms of Dementia in China From 1990 to 2019: An Age-Period-Cohort Study and Joinpoint Analysis
    Gao, Yongliang
    Liu, Xiaonan
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [29] Screening and early warning system for chronic obstructive pulmonary disease with obstructive sleep apnoea based on the medical Internet of Things in three levels of healthcare: protocol for a prospective, multicentre, observational cohort study
    Pan, Zihan
    Liao, Sha
    Sun, Wanlu
    Zhou, Haoyi
    Lin, Shuo
    Chen, Dian
    Jiang, Simin
    Long, Huanyu
    Fan, Jing
    Deng, Furong
    Zhang, Wenlou
    Chen, Baiqi
    Wang, Junyi
    Huang, Yongwei
    Li, Jianxin
    Chen, Yahong
    BMJ OPEN, 2024, 14 (02):
  • [30] Would transcranial direct current stimulation (tDCS) enhance the effects of working memory training in older adults with mild neurocognitive disorder due to Alzheimer's disease: study protocol for a randomized controlled trial
    Cheng, Calvin P. W.
    Chan, Sandra S. M.
    Mak, Arthur D. P.
    Chan, Wai Chi
    Cheng, Sheung Tak
    Shi, Lin
    Wang, Defeng
    Lam, Linda Chiu-Wa
    TRIALS, 2015, 16